NBI-1065845-MDD3027: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Maintenance of Effect of NBI 1065845 as an Adjunctive Treatment in Subjects with Major Depressive Disorder (MDD)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-520541-72-00

Acronym

NBI-1065845-MDD3027

Enrollment

158

Registered

2025-09-16

Start date

2025-10-22

Completion date

Unknown

Last updated

2025-12-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder

Brief summary

The primary endpoint for this study will be the time from randomization to relapse.

Interventions

DRUGNBI-1065845

DRUGIdentical to NBI-1065845 tablets without active drug

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The primary endpoint for this study will be the time from randomization to relapse.	—

Countries

Bulgaria, Estonia, Italy, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026